Biogen Idec Inc (BIIB) 330.48 $BIIB
Indexes Trim Losses But Remain Lower At Midday
at Investor's Business Daily - Fri Sep 05, 11:04AM CDT
The stock market came off morning lows at midday Friday, but remained lower as some notable leaders came under fire. The Nasdaq fell 0.3% while the S&P 500 and the Dow Jones industrial average were down 0.1%. Volume was running higher on the NYSE and...
Upcoming Conferences, Dividends, Regulatory Disclosures, and Acquisitions - Research Reports on Medtronic, Humana, Shire, Biogen and Covidien
PR Newswire - Fri Sep 05, 8:05AM CDT
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Humana Inc. (NYSE: HUM), Shire Plc (NASDAQ: SHPG), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6245-100free.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 2.70%
Comtex SmarTrend(R) - Thu Sep 04, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.78 to a high of $344.44. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $339.18 on volume of 827,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Diplomat to distribute Plegridy(TM) (peginterferon beta-1a) for treatment of multiple sclerosis
PR Newswire - Thu Sep 04, 3:42PM CDT
Diplomat, the nation's largest independent specialty pharmacy, announced that it will distribute Plegridy(TM) (peginterferon beta-1a). Manufactured by Biogen Idec, Plegridy(TM) was approved on August 15, 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS). Plegridy is the only pegylated beta interferon approved for use in RMS and is dosed once every two weeks. Plegridy can be administered subcutaneously with the Plegridy Pen, a new, ready-to-use autoinjector, or a prefilled syringe.
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
Specialty Vaccine Company PaxVax Appoints Mark Meltz Executive Vice President and Chief Legal Officer
Business Wire - Wed Sep 03, 7:01AM CDT
PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Mark Meltz as Executive Vice President and Chief Legal Officer. In this role, Mr. Meltz will oversee all legal, intellectual property, business development, government affairs, compliance and corporate governance matters for the company.
Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care
Business Wire - Wed Sep 03, 7:01AM CDT
--- Innovative Programs Reinforce Commitment to Improving the Lives of People Living with MS -
Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014
Business Wire - Tue Sep 02, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference 2014. The webcast will be live on Monday, September 8, 2014 at 2:00p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Watch For Today's Momo Momentum Stock: Biogen Idec (BIIB)
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple
Biogen: Moving From Collaboration To Innovation
at Investor's Business Daily - Fri Aug 29, 3:14PM CDT
In an industry as risky as biotechnology, it's easy to stick with a proven formula. But sometimes, managing for success means changing your strategic direction to avoid falling into a rut. After two decades of successfully collaborating with other...
Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical
PR Newswire Europe - Fri Aug 29, 7:37AM CDT
DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/z9b74c/global_multiple] has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/z9b74c/global_multiple] report to their offering.
US CNS Disorders Drug Pipeline Insight 2014
M2 - Fri Aug 29, 3:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j85brc/us_cns_disorders) has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market. Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each. Key Topics Covered: 1. Introduction to Central Nervous System (CNS) Disorder 2. US Central Nervous System (CNS) Disorder Market Overview 3. US Central Nervous System (CNS) Disorder Incidence by Disease 4. US Central Nervous System (CNS) Disorder Market Dynamics 5. US Multiple CNS Disorder Drug Pipeline by Phase & Company 6. US Alzheimer's Disease Drug Pipeline by Phase & Company 7. US Multiple Sclerosis Drug Pipeline by Phase & Company 8. US Parkinson's Disease Drug Pipeline by Phase & Company 9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company 10. US Epilepsy Drug Pipeline by Phase & Company 11. US Migraine Drug Pipeline by Phase & Company 12. US Huntington's Disease Drug Pipeline by Phase & Company 13. US Neuropathic Pain Clinical Pipeline by Phase & Company 14. US Schizophrenia Clinical Trial Insight by Phase & Company 15. US Sleep Disorders Drug Pipeline by Phase & Company 16. Competitive Landscape Companies Mentioned: - Alkermes - Allergan - AstraZeneca - Biogen Idec - Bristol-Myers Squibb - Eli Lilly - GlaxoSmithKline - Merck - Novartis - Pfizer - Roche - Sanofi - Sunovion Pharmaceuticals - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/j8..._disorders
Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
Biogen names Dr Donald R. Johns VP of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub)
M2 - Wed Aug 27, 5:48AM CDT
Medicine company Biogen (NasdaqGS:BIIB) disclosed on Tuesday that it has appointed Dr Donald R. Johns, MD as vice president of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub), a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS.
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
Indexes Trim Losses But Remain Lower At Midday
at Investor's Business Daily - Fri Sep 05, 11:04AM CDT
The stock market came off morning lows at midday Friday, but remained lower as some notable leaders came under fire. The Nasdaq fell 0.3% while the S&P 500 and the Dow Jones industrial average were down 0.1%. Volume was running higher on the NYSE and...
Upcoming Conferences, Dividends, Regulatory Disclosures, and Acquisitions - Research Reports on Medtronic, Humana, Shire, Biogen and Covidien
PR Newswire - Fri Sep 05, 8:05AM CDT
Today, Analysts Review released its research reports regarding Medtronic, Inc. (NYSE: MDT), Humana Inc. (NYSE: HUM), Shire Plc (NASDAQ: SHPG), Biogen Idec Inc. (NASDAQ: BIIB) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6245-100free.
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 2.70%
Comtex SmarTrend(R) - Thu Sep 04, 3:54PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.78 to a high of $344.44. Yesterday, the shares fell 2.7%, which took the trading range below the 3-day low of $339.18 on volume of 827,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Diplomat to distribute Plegridy(TM) (peginterferon beta-1a) for treatment of multiple sclerosis
PR Newswire - Thu Sep 04, 3:42PM CDT
Diplomat, the nation's largest independent specialty pharmacy, announced that it will distribute Plegridy(TM) (peginterferon beta-1a). Manufactured by Biogen Idec, Plegridy(TM) was approved on August 15, 2014 by the US Food and Drug Administration for the treatment of relapsing forms of multiple sclerosis (RMS). Plegridy is the only pegylated beta interferon approved for use in RMS and is dosed once every two weeks. Plegridy can be administered subcutaneously with the Plegridy Pen, a new, ready-to-use autoinjector, or a prefilled syringe.
RBCC Explores Novel Uses for New Naltrexone Delivery Protocols
Business Wire - Thu Sep 04, 4:00AM CDT
From chronic pain to obesity, new research suggests that there are practically no limits to the number of illnesses that the prescription drug Naltrexone can treat. Biotech company Rainbow Coral Corp. (OTCBB:RBCC) is working to make Naltrexone more effective than ever before.
5 Things Biogen Idec Inc's Management Wants You to Know
Brian Orelli, The Motley Fool - Motley Fool - Wed Sep 03, 8:17AM CDT
Biogen Idec held a conference call to go along with the release of second quarter earnings. Here are five things that management said on the call about Biogen Idec's ongoing prospects (quotes courtesy of S&P Capital IQ ). George Scangos...
Specialty Vaccine Company PaxVax Appoints Mark Meltz Executive Vice President and Chief Legal Officer
Business Wire - Wed Sep 03, 7:01AM CDT
PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the appointment of Mark Meltz as Executive Vice President and Chief Legal Officer. In this role, Mr. Meltz will oversee all legal, intellectual property, business development, government affairs, compliance and corporate governance matters for the company.
Biogen Idec Data at Joint ACTRIMS-ECTRIMS Meeting Highlight Robust Multiple Sclerosis Portfolio and Commitment to Advancing Patient Care
Business Wire - Wed Sep 03, 7:01AM CDT
--- Innovative Programs Reinforce Commitment to Improving the Lives of People Living with MS -
Biogen Idec to Present at the Morgan Stanley Global Healthcare Conference 2014
Business Wire - Tue Sep 02, 3:01PM CDT
Biogen Idec Inc. (NASDAQ: BIIB) announced today that it will present at the Morgan Stanley Global Healthcare Conference 2014. The webcast will be live on Monday, September 8, 2014 at 2:00p.m. ET. To access the live webcast, please visit Biogen Idec's Investors section at www.biogenidec.com. An archived version of the webcast will be available for 14 days following the presentation.
Watch For Today's Momo Momentum Stock: Biogen Idec (BIIB)
at The Street - Tue Sep 02, 8:47AM CDT
Trade-Ideas LLC identified Biogen Idec (BIIB) as a momo momentum candidate
Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical
M2 - Mon Sep 01, 5:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vfkpw2/global_multiple) has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering. The Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis. One of the emerging trends in the market is the introduction of disease-modifying drugs as a treatment option. Drugs such as Copaxone (Glatiramer Acetate) by Teva Pharmaceuticals and Tysabri (Natalizumab) by Biogen Idec are increasingly used in the treatment of multiple sclerosis. According to the report, the launch of products for treating multiple sclerosis is expected to drive the market during the forecast period of 2013-2018. There is a lucrative space for companies that can address the issue of unmet medical needs in the market. Further, the report states that one of the major challenges in the Global Multiple Sclerosis Drugs market is the unknown etiology of the disease. This has made difficult for medical researchers to develop drugs that target the main source of the disease. Key Questions Answered in this Report - What will the market size be in 2018 and what will the growth rate be? - What are the Key Market Trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? Market Drivers/Challenges/Trends - Unmet Medical Needs - Unknown Etiology of the Disease - Introduction of Disease-modifying Drugs Key Vendors - Bayer - Biogen Idec - Merck Serono - Novartis - Teva Pharmaceutical Other Prominent Vendors - AB Science - Abbvie - Acorda - Active Biotech - GlaxoSmithKline - Glenmark - Mitsubishi Tanabe - Opexa - Pfizer - Sanofi For more information visit http://www.researchandmarkets.com/research/vf...l_multiple
Biogen: Moving From Collaboration To Innovation
at Investor's Business Daily - Fri Aug 29, 3:14PM CDT
In an industry as risky as biotechnology, it's easy to stick with a proven formula. But sometimes, managing for success means changing your strategic direction to avoid falling into a rut. After two decades of successfully collaborating with other...
Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical
PR Newswire Europe - Fri Aug 29, 7:37AM CDT
DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets [http://www.researchandmarkets.com/research/z9b74c/global_multiple] has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/z9b74c/global_multiple] report to their offering.
US CNS Disorders Drug Pipeline Insight 2014
M2 - Fri Aug 29, 3:24AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j85brc/us_cns_disorders) has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering. The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market. Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each. Key Topics Covered: 1. Introduction to Central Nervous System (CNS) Disorder 2. US Central Nervous System (CNS) Disorder Market Overview 3. US Central Nervous System (CNS) Disorder Incidence by Disease 4. US Central Nervous System (CNS) Disorder Market Dynamics 5. US Multiple CNS Disorder Drug Pipeline by Phase & Company 6. US Alzheimer's Disease Drug Pipeline by Phase & Company 7. US Multiple Sclerosis Drug Pipeline by Phase & Company 8. US Parkinson's Disease Drug Pipeline by Phase & Company 9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company 10. US Epilepsy Drug Pipeline by Phase & Company 11. US Migraine Drug Pipeline by Phase & Company 12. US Huntington's Disease Drug Pipeline by Phase & Company 13. US Neuropathic Pain Clinical Pipeline by Phase & Company 14. US Schizophrenia Clinical Trial Insight by Phase & Company 15. US Sleep Disorders Drug Pipeline by Phase & Company 16. Competitive Landscape Companies Mentioned: - Alkermes - Allergan - AstraZeneca - Biogen Idec - Bristol-Myers Squibb - Eli Lilly - GlaxoSmithKline - Merck - Novartis - Pfizer - Roche - Sanofi - Sunovion Pharmaceuticals - Teva Pharmaceutical For more information visit http://www.researchandmarkets.com/research/j8..._disorders
Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - ZACKS - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
After Recent Surge, Are Biotech ETFs Back on Track? - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 27, 7:00AM CDT
Recent trends have been very favorable for the biotech sector, but can this run continue?
Biogen names Dr Donald R. Johns VP of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub)
M2 - Wed Aug 27, 5:48AM CDT
Medicine company Biogen (NasdaqGS:BIIB) disclosed on Tuesday that it has appointed Dr Donald R. Johns, MD as vice president of its amyotrophic lateral sclerosis (ALS) Innovation Hub (ALS iHub), a new, cohesive unit dedicated to accelerating the discovery and development of novel therapies for ALS.
Celgene, Gilead Lead Big Biotech Stock Movers
at Investor's Business Daily - Tue Aug 26, 4:55PM CDT
Big-cap biotechs moved in strong volume on the stock market today as Deutsche Bank added several to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst...
